Page 179 - 80_01

Dry
eye
disease
compounds…

omega-3 and omega-6 fatty acids on a conjunctival inflammatory marker in dry eye
patients. Acta Ophthalmol. 89(7), e591-7 (2011).
37. Rand AL, Asbell PA. Nutritional supplements for dry eye syndrome. Curr Opin
Ophthalmol. 22(4), 279-82 (2011).
38. Steven P, Cursiefen C. (Anti-inflammatory treatment in dry eye disease). Klin
Monbl Augenheilkd. 229(5), 500-5 (2012).
39. Axtell RC, Steinman L, Han MH, et al. Markers for determination of patient
responsiveness. US20110250206, US20110243893 (2011)
40. Dhimolea E. Canakinumab. MAbs. 2(1), 3-13 (2010).
41. Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody
to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med.
2(52), 52ra72 (2010).
42. Patel DD, Lee DM, Kolbinger F, et al. Effect of IL-17A blockade with
secukinumab in autoimmune diseases. Ann Rheum Dis. (2012).
43. Cumberlidge G, Lama T, Meerovitch K. Beta-turn peptidomimetic cyclic
compounds for treating dry eye. US20128293713 (2012)
44. Wang ZX, Sun XG. (The effect of nerve growth factor on proliferation and
expression of mucin gene in human conjunctival goblet cells). Zhonghua Yan Ke Za
Zhi. 43(10), 928-31 (2007).
45. Jain P, Li R, Lama T, et al. An NGF mimetic, MIM-D3, stimulates conjunctival
cell glycoconjugate secretion and demonstrates therapeutic efficacy in a rat model of
dry eye. Exp Eye Res. 93(4), 503-12 (2011).
46. Meerovitch K, Torkildsen G, Lonsdale J, et al. Safety and efficacy of MIM-D3
ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in
patients with dry eye. Clin Ophthalmol. 7 1275-85 (2013).
47. Boltralik JJ. Anti-inflammatory compounds for ophthalmic use.
US19955446177 (1995)
48. Mulki L, Foster CS. Difluprednate for inflammatory eye disorders. Drugs Today
(Barc). 47(5), 327-33 (2011).
49. Viiri J, Jauhonen HM, Kauppinen A, et al. Cis-urocanic acid suppresses UV-B-
induced interleukin-6 and -8 secretion and cytotoxicity in human corneal and
conjunctival epithelial cells in vitro. Mol Vis. 15 1799-805 (2009).
50. Jauhonen HM, Kauppinen A, Paimela T, et al. Cis-urocanic acid inhibits
SAPK/JNK signaling pathway in UV-B exposed human corneal epithelial cells in vitro.
Mol Vis. 17 2311-7 (2011).
51. Sosne G, Crockford D. Methods and compositions for stabilizing polypeptides.
WO2008108927 (2008)
52. Golstein AL, Sosne G. Methods of treating disorders of the eye and surrounding
tissue with thymosin beta 4 (Tb4), analogues, isoforms and other derivatives
US20110020449 (2011)
53. Philp D, Kleinman HK. Animal studies with thymosin beta, a multifunctional
tissue repair and regeneration peptide. Ann N Y Acad Sci. 1194 81-6 (2010).
54. Sosne G, Qiu P, Ousler GW, 3rd, et al. Thymosin beta4: a potential novel dry
eye therapy. Ann N Y Acad Sci. 1270 45-50 (2012).
55. Sosne G, Crockford D, Finkelstein JJ, et al., editors. Single-Center Study
Evaluating the Safety and Efficacy of 0.1% Tß4 Ophthalmic Solution Compared to

175